Morphine Increases Platelet Reactivity in Infarctions

The use of morphine in patients undergoing ST elevation acute coronary syndromes is associated to higher platelet reactivity and lower thrombolysiscapacity, according to this small study. The negative effects seem to resolve 2 days after administration.

This transient effect is believed to be the result of the inhibition of the normal muscular activity of the stomach caused by morphine, which in turn delays antiplatelet medication absorption.

Morphine is recommended by the guidelines as the preferred drug to alleviate pain in patients undergoing ST elevation AMI, but there is enough evidence to support the fact that it may alter medication administered orally, particularly antiplatelets.

The study included 125 consecutive patients presenting with acute myocardial infarction; 101 received morphine in the ambulance and 24 did not. They were all loaded with 300 mg of aspirin and 600 mg clopidogrel or 180 mg ticagrelor before primary PCI.

Blood was extracted at admission and at 2 days, when it was observed patients receiving morphine had significantly higher platelet reactivity and also longer lysis time.

Despite this, there were no differences in clinical events,but the study did not have statistical power to show this.

More articles by this author

PARTNER 2A: TAVI Not Inferior to Surgery in Intermediate Risk Patients

Transcatheter aortic valve replacement (TAVI) with the new generation balloon expandable valve is at least as good as surgery in intermediate risk patients with...

The SAPIEN 3 Valve Resulted Superior to Surgery in an Observational Study

The last generation of the balloon expandable valve resulted superior to surgery in intermediate riskpatients, in a registry analyzis. Patients treated with the SAPIEN...

CoreValve US Pivotal: at 3 Years, the Self-Expanding Valve Maintains Its Advantage vs. Surgery

At 3 year follow up, the CoreValve US Pivotal study on high risk elderly patients, the self-expanding valve showed a lasting benefit vs. surgery. These...

PARTNER 1 in +90 Year Old Patients: TAVI and the Age Paradox

A new analyzis of the PARTNER 1 trial showed that patients over 90 undergoing transcatheter aortic valve replacement (TAVI) show no increase in mortality...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...